Jump to content

European Federation of Pharmaceutical Industries and Associations: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
Oleginger (talk | contribs)
fixed links in References
EFPIA (talk | contribs)
No edit summary
Line 1: Line 1:
[[Image:EFPIA_Logo_LR_070416.jpg|thumb|200px|right|Logo]]
[[Image:EFPIA_Logo_LR_070416.jpg|thumb|200px|right|Logo]]
The '''European Federation of Pharmaceutical Industries and Associations''' or '''EFPIA''' is the organization representing the research-based pharmaceutical industry operating in [[Europe]]. The EFPIA was created in 1978. <ref> [http://www.medicalnewstoday.com/articles/112414.php ''30 Years Contributing To The Health And Wealth Of EU Citizens''], Medical News Today, 23 June 2008. Consulted on July 26, 2008. </ref>
The 'European Federation of Pharmaceutical Industries and Associations' or 'EFPIA' represents the research-based pharmaceutical industry operating in Europe. Through its direct membership of 32 national associations and 43 leading pharmaceutcial companies, EFPIA is the voice on the EU scene of 2.200 companies committed to researching, developing and bringing to patients new medicines that improve health and the quality of life around the world.

The EFPIA has a direct membership of 30 national pharmaceutical industry associations and in addition 45 individual pharmaceutical companies. The EFPIA as such represents 2,100 research-based pharmaceutical companies in Europe.


<blockquote>
''"Over the past 30 years, the federation’s member companies and associations have been striving to shape the right framework for our industry to thrive and thus keep contributing to advances in science, innovation and patient wellbeing in Europe."'' Arthur J. Higgins - EFPIA President - Chairman of the Bayer HealthCare Executive
EFPIA Annual Meetings 2008 - Press Conference Speech (Paris, June 2008)
</blockquote>
Some of the EFPIA members are: [[Abbott Laboratories]],
Some of the EFPIA members are: [[Abbott Laboratories]],
[[Akzo Nobel]],
[[Akzo Nobel]],

Revision as of 12:33, 20 October 2008

File:EFPIA Logo LR 070416.jpg
Logo

The 'European Federation of Pharmaceutical Industries and Associations' or 'EFPIA' represents the research-based pharmaceutical industry operating in Europe. Through its direct membership of 32 national associations and 43 leading pharmaceutcial companies, EFPIA is the voice on the EU scene of 2.200 companies committed to researching, developing and bringing to patients new medicines that improve health and the quality of life around the world.

"Over the past 30 years, the federation’s member companies and associations have been striving to shape the right framework for our industry to thrive and thus keep contributing to advances in science, innovation and patient wellbeing in Europe." Arthur J. Higgins - EFPIA President - Chairman of the Bayer HealthCare Executive EFPIA Annual Meetings 2008 - Press Conference Speech (Paris, June 2008)

Some of the EFPIA members are: Abbott Laboratories, Akzo Nobel, Almirall, Amgen, AstraZeneca, Baxter International, Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi Farmaceutici, Eli Lilly and Company, Ēzai, Esteve, Genzyme, Gilead Science, GlaxoSmithKline, Grünenthal, Ipsen Group, Johnson & Johnson, Lundbeck, Menarini, Merck KGaA, Merck & Co., Inc., Novartis, Novo Nordisk, Nycomed, Orion Oyj, Pfizer, Laboratoires Pierre Fabre, Procter & Gamble, Hoffmann-La Roche, sanofi-aventis, Schering-Plough, Servier, Sigma-Tau, Solvay, Takeda Pharmaceutical Company, UCB S.A. and Wyeth.

In May 2008 EFPIA together with the European Commission[1] launched the Innovative Medicines Initiative[2] (IMI) Joint Undertaking (JU) to strengthen the position of Europe in pharmaceutical research. The aim of IMI is to support the faster discovery and development of better medicines for patients and to enhance Europe’s competitiveness by ensuring that its biopharmaceutical sector remains a dynamic high-technology sector. The JU was initiated based on the positive experience in joint research activities during the InnoMed [3] Integrated Project, a pilot funded under the European Commission’s Sixth Framework Programme, with the two sub-projects InnoMed AddNeuroMed and InnoMed PredTox[4].

References

See also